<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583046</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-0722</org_study_id>
    <nct_id>NCT04583046</nct_id>
  </id_info>
  <brief_title>Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation</brief_title>
  <official_title>Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One lung ventilation (OLV) is essential during thoracic surgery. During OLV, intrapulmonary&#xD;
      shunt can be increased resulting hypoxemia. Although OLV technique had been advanced so far,&#xD;
      hypoxemia during OLV reaches about 10% in spite of inspired oxygen fraction 100%. Iloprost is&#xD;
      a prostaglandin analogue used for pulmonary hypertension, which can decrease pulmonary artery&#xD;
      resistance by selectively dilating pulmonary artery. In this prospective, randomized, double&#xD;
      blind study, the investigator is planning to investigate the effects of iloprost on&#xD;
      respiratory physiology (intrapulmonary shunt, deadspace, oxygenation, etc) in obese patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Result of arterial blood gas analysis : partial pressure of oxygen(PaO2)</measure>
    <time_frame>20 minutes after iloprost inhalation (T2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Result of arterial blood gas analysis : partial pressure of oxygen in the arterial blood(PaO2)/Fraction of inspired oxygen(FiO2) ratio (P/F ratio)</measure>
    <time_frame>20 minutes after iloprost inhalation (T2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Result of arterial blood gas analysis : Oxygen saturation in arterial blood(SaO2)</measure>
    <time_frame>20 minutes after iloprost inhalation (T2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>deadspace</measure>
    <time_frame>20 minutes after iloprost inhalation (T2)</time_frame>
    <description>Dead space ventilation was calculated with Paco2 and end-tidal carbon dioxide (Etco2) according to the Hardman and Aitkenhead equation [1.14 Ã— (Paco2- Etco2)/Paco2 - 0.005].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intrapulmonary shunt</measure>
    <time_frame>20 minutes after iloprost inhalation (T2)</time_frame>
    <description>-Shunt fraction (Qs/Qt) was calculated using the following formula: Qs/Qt = (CcO2-CaO2)/(CcO2-CvO2), (1)&#xD;
-whereby:&#xD;
CaO2 = (PaO2 x 0.0031) + (Hemoglobin x 1.36 x SaO2), (2)&#xD;
CvO2 = (PvO2 x 0.0031) + (Hemoglobin x 1.36 x SvO2), (3)&#xD;
CcO2 = ([FiO2 x (PB - PH2O) - PaCO2/Respiratory quotient] x 0.0031) + (Hemoglobin x 1.36), (4)&#xD;
PB is the barometric pressure (760 mmHg), the PH2O is 47 mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Lung Cancer (Including Metastatic Cancer)</condition>
  <condition>Pulmonary Infection</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline inhalation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iloprost group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iloprost inhalation group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline inhalation</intervention_name>
    <description>When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iloprost inhalation</intervention_name>
    <description>When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).</description>
    <arm_group_label>iloprost group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. scheduled for VATS lobectomy&#xD;
&#xD;
          2. 40 &lt; age &lt; 80&#xD;
&#xD;
          3. American Society of Anaesthesiologists(ASA) physical status classification I~III&#xD;
&#xD;
          4. BMI &gt; 30 kg /m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. American Society of Anaesthesiologists(ASA) physical status classification IV or more&#xD;
&#xD;
          2. NYHA class III~IV&#xD;
&#xD;
          3. Severe obstructive lung disease and/or restrictive lung disease patients&#xD;
&#xD;
          4. patients with end-organ diseases (i.e. heart failure, respiratory failure, hepatic&#xD;
             failure, renal failure)&#xD;
&#xD;
          5. arrhythmia&#xD;
&#xD;
          6. pregnant women&#xD;
&#xD;
          7. pulmonary edema or pulmonary arterial hypertension&#xD;
&#xD;
          8. cerebrovascular disease&#xD;
&#xD;
          9. unstable angina or myocardial infarction within 6 months&#xD;
&#xD;
         10. patients with allergic reaction at iloprost&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Jun Oh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Jun Oh</last_name>
    <phone>+82-2-2228-2423</phone>
    <email>yjoh@yuhs.ac</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>October 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 4, 2020</last_update_submitted>
  <last_update_submitted_qc>October 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

